University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Uma Mahadevan, M.D.


An expert in inflammatory bowel disease, particularly as it relates to pregnancy and fertility, new drug trials and pouchitis, Dr. Uma Mahadevan serves as co-medical director of the UCSF Center for Colitis and Crohn's disease. In addition to caring for patients with inflammatory bowel disease (IBD), she is interested in developing novel therapies for the condition, as well as investigating pregnancy and fertility outcomes in IBD.

Mahadevan received her medical degree from State University of New York and completed her residency in internal medicine at Mount Sinai Medical Center in New York. She then went on to complete her fellowship in gastroenterology at UCSF and in inflammatory bowel disease at Mayo Clinic, Rochester, Minn. Her research on inflammatory bowel disease has been widely published in medical journals and books. Currently, Mahadevan holds the position of professor of clinical medicine at UCSF.


Colitis and Crohn's Disease Center
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Gastroenterology at Mount Zion
1701 Divisadero St., Suite 120
San Francisco, CA 94115
Phone: (415) 502-4444
Fax: (415) 502-2249

Hours: Monday to Friday
9 a.m. – 4:30 p.m.

Conditions & Treatments

  • Microscopic Colitis
  • Pouchitis

More about Uma Mahadevan

Additional Languages



State University of New York, Brooklyn College of Medicine 1995


Mount Sinai Medical Center, Internal Medicine 1998


UCSF Medical Center, Gastroenterology 2001
Mayo Clinic, Inflammatory Bowel Disease 2001

Selected Research and Publications

  1. Mahadevan U, Matro R. Care of the Pregnant Patient With Inflammatory Bowel Disease. Obstet Gynecol. 2015 Aug; 126(2):401-12.
  2. Kattah MG, Mahadevan U. Confocal laser endomicroscopy for membrane-bound tumor necrosis factor predicts response to therapy in Crohn's disease. Gastroenterology. 2015 May; 148(5):1067-9.
  3. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GD, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings from the american college of rheumatology reproductive health summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015 Mar; 67(3):313-25.
  4. Matro R, Mahadevan U. Editorial: the management of IBD during pregnancy and lactation. Aliment Pharmacol Ther. 2014 Nov; 40(10):1247-8.
  5. Huang VW, Mahadevan U. A measured approach to Crohn's therapy: check levels and save. Gastroenterology. 2014 Nov; 147(5):1174-5.
  6. Lin K, Mahadevan U. Pharmacokinetics of biologics and the role of therapeutic monitoring. Gastroenterol Clin North Am. 2014 Sep; 43(3):565-79.
  7. Kattah MG, Mahadevan U. Insights into the molecular pathophysiology of inflammatory bowel disease: ATG16L1 suppresses nod-driven inflammation. Gastroenterology. 2014 Aug; 147(2):528-30.
  8. Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol. 2014 May; 26(3):347-53.
  9. Hwang C, Ross V, Mahadevan U. Popular exclusionary diets for inflammatory bowel disease: the search for a dietary culprit. Inflamm Bowel Dis. 2014 Apr; 20(4):732-41.
  10. Shah S, Terdiman J, Gundling K, Mahadevan U. Immunoglobulin therapy for refractory Crohn's disease. Therap Adv Gastroenterol. 2014 Mar; 7(2):99-102.
  11. Ng SW, Mahadevan U. My treatment approach to management of the pregnant patient with inflammatory bowel disease. Mayo Clin Proc. 2014 Mar; 89(3):355-60.
  12. Lin KK, Mahadevan U. Etrolizumab: anti-ß7-a novel therapy for ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):307-9.
  13. Truta B, Li DX, Mahadevan U, Fisher ER, Chen YY, Grace K, Velayos F, Terdiman JP. Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci. 2014 Jan; 59(1):135-45.
  14. Sheibani S, Mahadevan U. Editorial: Are thiopurines and anti-TNFa agents safe to use in pregnant patients with inflammatory bowel disease? Am J Gastroenterol. 2013 Mar; 108(3):441-3.
  15. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013 Feb; 9(2):161-73; quiz 174.
  16. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jan; 19(1):15-22.
  17. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.
  18. Pak S, Holland N, Garnett EA, Mileti E, Mahadevan U, Beckert R, Kanwar B, Heyman MB. Cytokine profiles in peripheral blood of children and adults with Crohn disease. J Pediatr Gastroenterol Nutr. 2012 Jun; 54(6):769-75.
  19. Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis. 2012 Oct; 18(10):1961-81.
  20. Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Bañares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011 Dec; 5(6):612-8.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.